SEC Form 4 · accession 0001209191-18-036511
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ashraf Amanullah
Officer — See Remarks
Period of report
May 31, 2018
Accepted (ET)
Jun 7, 2018 · 7:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 31, 2018 | M | 3,333 | $0.00 | A | 26,264 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3 | $0.00 | May 31, 2018 | M | 3,333 | A | — | — | Common Stock | 3,333 | 3,333 | D |
Explanation of responses
- F1Represent shares acquired upon vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017.
- F2Includes 2,500, 2,500, 2,499 and 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on November 15, 2016, May 15, 2017, November 15, 2017, and May 15, 2018, respectively, each in a transaction exempt under Rule 16b-3.
- F3The RSU grant vests as to one-third (1/3) of the total number of units on each one year anniversary of the the grant commencing of February 7, 2018. Vesting was accelerated to May 31, 2018 pursuant to the Company's Executive Severance and Change In Control Policy.
Remarks
Senior Vice President, Biologics Development and Manufacturing